[1] R.N. Foley, P.S. Parfrey, M.J. Sarnak, Clinical epidemiology of cardiovascular disease in chronic renal disease, Am. J. Kidney Dis. 32 (1998) 112e119.
[2] B.F. Culleton, M.G. Larson, P.W. Wilson, J.C. Evans, P.S. Parfrey, D. Levy, Car- diovascular disease and mortality in a community-based cohort with mild renal insufficiency, Kidney Int. 56 (1999) 2214e2219.
[3] A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, C.Y. Hsu, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med. 351 (2004) 1296e1305.
[4] D. Russo, G. Palmiero, A.P. De Blasio, M.M. Balletta, V.E. Andreucci, Coronary artery calcification in patients with CRF not undergoing dialysis, Am. J. Kidney Dis. 44 (2004) 1024e1030.
[5] E.L. Schiffrin, M.L. Lipman, J.F. Mann, Chronic kidney disease: effects on the cardiovascular system, Circulation 116 (2007) 85e97.
[6] W.G. Goodman, Vascular calcification in chronic renal failure, Lancet 358 (2001) 1115e1116.
[7] K. Hruska, S. Mathew, R. Lund, Y. Fang, T. Sugatani, Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int. 79 (2011) S9eS13.
[8] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney Int. Suppl. 3 (2013) 1e150.
[9] A. Akbari, C.M. Clase, P. Acott, M. Battistella, A. Bello, P. Feltmate, A. Grill, M. Karsanji, P. Komenda, F. Madore, B.J. Manns, S. Mahdavi, R.A. Mustafa, A. Smyth, E.S. Welcher, Canadian society of nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management, Am. J. Kidney Dis. 65 (2) (2015) 177e205.
[10] H. Taniwaki, E. Ishimura, T. Tabata, Y. Tsujimoto, A. Shioi, T. Shoji, M. Inaba, T. Inoue, Y. Nishizawa, Aortic calcification in haemodialysis patients with diabetes mellitus, Nephrol. Dial. Transpl. 20 (11) (2005) 2472e2478.
[11] Y. Tatami, Y. Yasuda, S. Suzuki, H. Ishii, A. Sawai, Y. Shibata, T. Ota, K. Shibata, M. Niwa, R. Morimoto, M. Hayashi, S. Kato, S. Maruyama, T. Murohara, Impact of abdominal aortic calcification on long-term cardiovascular outcomes in patients with chronic kidney disease, Atherosclerosis 243 (2) (2015) 349e355.
[12] S. Matsuo, E. Imai, M. Horio, Y. Yasuda, K. Tomita, K. Nitta, K. Yamagata, Y. Tomino, H. Yokoyama, A. Hishida, Collaborators developing the Japanese equation for estimated GFR. revised equations for estimated GFR from serum creatinine in Japan, Am. J. Kidney Dis. 53 (2009) 982e992.
[13] A.S. Levey, P.E. de Jong, J. Coresh, M. El Nahas, B.C. Astor, K. Matsushita, R.T. Gansevoort, B.L. Kasiske, K.U. Eckardt, The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report, Kidney Int. 80 (2011) 17e28.
[14] T. Ogihara, K. Kikuchi, H. Matsuoka, T. Fujita, J. Higaki, M. Horiuchi, Y. Imai, T. Imaizumi, S. Ito, H. Iwao, K. Kario, Y. Kawano, S. Kim-Mitsuyama, G. Kimura, H. Matsubara, H. Matsuura, M. Naruse, I. Saito, K. Shimada, K. Shimamoto, H. Suzuki, S. Takishita, N. Tanahashi, T. Tsuchihashi, M. Uchiyama, S. Ueda, H. Ueshima, S. Umemura, T. Ishimitsu, H. Rakugi, Japanese society of hyper- tension committee. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009), Hypertens. Res. 32 (1) (2009) 3e107.
[15] S.C. Palmer, A. Hayen, P. Macaskill, F. Pellegrini, J.C. Craig, G.J. Elder, G.F. Strippoli, Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis, JAMA 305 (2011) 1119e1127.
[16] J. Floege, J. Kim, E. Ireland, C. Chazot, T. Drueke, A. de Francisco, F. Kronenberg, D. Marcelli, J. Passlick-Deetjen, G. Schernthaner, B. Fouqueray, D.C. Wheeler, ARO Investigators: serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population, Nephrol. Dial. Transpl. 26 (2011) 1948e1955.
[17] C. An, H.J. Lee, H.S. Lee, S.S. Ahn, B.W. Choi, M.J. Kim, Y.E. Chung, CT-based abdominal aortic calcification score as a surrogate marker for predicting the presence of asymptomatic coronary artery disease, Eur. Radiol. 24 (2014) 2491e2498.
[18] Y. Takayama, Y. Yasuda, S. Suzuki, Y. Shibata, Y. Tatami, K. Shibata, M. Niwa, A. Sawai, R. Morimoto, S. Kato, H. Ishii, S. Maruyama, T. Murohara, Relation- ship between abdominal aortic and coronary artery calcification as detected by computed tomography in chronic kidney disease patients, Heart Vessels. 31 (7) (2016) 1030e1037.
[19] C.W. Tsao, K.M. Pencina, J.M. Massaro, E.J. Benjamin, D. Levy, R.S. Vasan, U. Hoffmann, C.J. O'Donnell, G.F. Mitchell, Cross-sectional relations of arterial stiffness, pressure pulsatility, wave reflection, and arterial calcification, Arte- rioscler. Thromb. Vasc. Biol. 34 (11) (2014) 2495e2500.
[20] T. Adragao, A. Pires, P. Branco, R. Castro, A. Oliveira, C. Nogueira, J. Bordalo, J.D. Curto, M.M. Prata, Ankleebrachial index, vascular calcifications and mortality in dialysis patients, Nephrol. Dial. Transpl. 27 (1) (2012) 318e325.
[21] S. Hanada, R. Ando, S. Naito, N. Kobayashi, M. Wakabayashi, T. Hata, S. Sasaki, Assessment and significance of abdominal aortic calcification in chronic kid- ney disease, Nephrol. Dial. Transpl. 25 (6) (2010) 1888e1895.
[22] M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson, American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical car- diology, and epidemiology and prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention, Circulation 108 (2003) 2154e2169.
[23] E. Imai, S. Ito, M. Haneda, A. Harada, F. Kobayashi, T. Yamasaki, H. Makino, J.C. Chan, Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure), Nephrol. Dial. Transpl. 31 (3) (2016) 447e454.
[24] J.L. Megnien, A. Simon, M. Lemariey, M.C. Plainfosse, J. Levenson, Hypertens promotes coronary calcium deposit in asymptomatic men, Hypertension 27 (1996) 949e954.
[25] Y. Miwa, M. Tsushima, H. Arima, Y. Kawano, T. Sasaguri, Pulse pressure is an independent predictor for the progression of aortic wall calcification in pa- tients with controlled hyperlipidemia, Hypertension 43 (3) (2004) 536e540.
[26] M.K. Osako, H. Nakagami, M. Shimamura, H. Koriyama, F. Nakagami, H. Shimizu, T. Miyake, M. Yoshizumi, H. Rakugi, R. Morishita, Cross-talk of receptor activator of nuclear factor-kB ligand signaling with renin-angiotensin system in vascular calcification, Arterioscler. Thromb. Vasc. Biol. 33 (6) (2013) 1287e1296.
[27] M.C. Hu, M. Shi, J. Zhang, H. Quinones, C. Griffith, M. Kuro-o, O.W. Moe, Klotho deficiency causes vascular calcification in chronic kidney disease, J. Am. Soc. Nephrol. 22 (2011) 124e136.
[28] M. Schoppet, L.C. Hofbauer, N. Brinskelle-Schmal, A. Varennes, J. Goudable, M. Richard, G. Hawa, R. Chapurlat, P. Szulc, Serum level of the phosphaturic factor fgf23 is associated with abdominal aortic calcification in men: the strambo study, J. Clin. Endocrinol. Metab. 97 (2012) 575e583.
[29] T. Isakova, P. Wahl, G.S. Vargas, O.M. Gutie´rrez, J. Scialla, H. Xie, D. Appleby, L. Nessel, K. Bellovich, J. Chen, L. Hamm, C. Gadegbeku, E. Horwitz, R.R. Townsend, C.A. Anderson, J.P. Lash, C.Y. Hsu, M.B. Leonard, M. Wolf, Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease, Kidney Int. 79 (2011) 1370e1378.
[30] H.H. Malluche, G. Blomquist, M.C. Monier-Faugere, T.L. Cantor, D. Davenport, High parathyroid hormone level and osteoporosis predict progression of coronary artery calcification in patients on dialysis, J. Am. Soc. Nephrol. 26 (10) (2015) 2534e2544.
[31] L. Di Lullo, A. Gorini, A. Bellasi, L.F. Morrone, R. Rivera, L. Russo, A. Santoboni, D. Russo, Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease, Clin. Kidney J. 8 (6) (2015) 732e736.
[32] S. Mathew, R.J. Lund, L.R. Chaudhary, T. Geurs, K.A. Hruska, Vitamin D receptor activators can protect against vascular calcification, J. Am. Soc. Nephrol. 19 (2008) 1509e1519.
[33] G.M. Chertow, S.K. Burke, P. Raggi, Treat to goal working group. sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients, Kidney Int. 62 (1) (2002) 245e252.
[34] T.B. Drüeke, Calcimimetics and outcomes in CKD, Kidney Int. Suppl. 3 (2013) 431e435.
[35] T. Nakano, T. Ninomiya, S. Sumiyoshi, H. Fujii, Y. Doi, H. Hirakata, K. Tsuruya, M. Iida, Y. Kiyohara, K. Sueishi, Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the hisayama study, Am. J. Kidney Dis. 55 (2010) 21e30.
[36] T.J. Ryan, W.B. Bauman, J.W. Kennedy, D.J. Kereiakes, S.B. King 3rd, B.D. McCallister, S.C. Smith Jr., D.J. Ullyot, Guidelines for percutaneous trans- luminal coronary angioplasty. a report of the american heart association/ american college of Cardiology task force on assessment of diagnostic and therapeutics cardiovascular procedures (committee on percutaneous trans- luminal coronary angioplasty), Circulation 88 (1993) 2987e3007.
[37] C. Rigatto, A. Levin, A.A. House, B. Barrett, E. Carlisle, A. Fine, Atheroma pro- gression in chronic kidney disease, Clin. J. Am. Soc. Nephrol. 4 (2009) 291e298.